index - Epidemiology in dermatology and evaluation of therapeutics

DOCUMENTS

95

 

NOTICES

156

 

 

MOTS CLES

Glucocorticoids Anticancer drugs Prostate cancer Drug survival Antimicrobiens Immune-related adverse events Acute Myeloid Leukaemia AML Antibiotic misuse Anti-Bacterial Agents Alcohol Alitretinoin Biologic Atrial fibrillation Pharmacoepidemiology Sacroiliitis Psoriasis Ankylosing spondylitis Biologic drug Anxiety Apremilast Cancer Anxiété Pregnancy Arthritis Antimicrobial resistance Stability Atopic dermatitis Biosimilar Pharmaceuticals Biological Therapy Angiotensin-converting enzyme inhibitors Quality of life Arrhythmia Etanercept Ethics Burden BTK protein Biologics Biomédicaments Sipuleucel-T Psoriatic arthritis Adalimumab Immune checkpoint inhibitors Amyloidosis Spondyloarthritis Auto-immune hepatitis Access to care Azathioprine Autoimmune diseases Cardiotoxicity Anti-TNF Angiotensin receptor blockers Intensive care Drug reaction Méta-Analyse Accelerometer Apre-milast Cardiomyopathy Network meta-analysis Management Biomarkers Biologic therapy Ankylosing Dermatology Aging Bacterial rhinosinusitis Pharmacovigilance Antibiotics Beta-lactam antibiotics Cardio-oncology ASDAS Infliximab Axial spondyloarthritis Placebo Auto-Diagnostic COVID-19 Treatment Vigibase® Antibiotic resistance Pharmaco-Épidémiologie Adverse side effects Systematic review Antimicrobial Stewardship Autoimmunity Immunotherapy Primary adrenal insufficiency Epidemiology Addiction Endocrine toxicity Antimicrobials Bacterial Ustekinumab Spondylitis Meta-Analysis Graft-versus-host disease Abus d'antibiotiques Anti-HCV Direct Acting Antivirals DAA Biological therapy Albinism ArtThese Adolescent

 

 

 

Epidemiology in Dermatology and Evaluation of therapeutics , EA 7379

Adresse

Université Paris-Est Créteil Val de Marne (UPEC)

Campus Centre de Créteil
61 Avenue du Général de Gaulle
94010 Créteil Cedex

Courriel

emilie.sbidian@aphp.fr

Site Internet

 

Rattachement(s)

UFR de Santé

Direction

Émilie SBIDIAN

 

Axe(s) de recherche

 


[legende-image]65[/legende-image] Axe 1 : Comment mieux gérer les patients ayant développé des réactins graves aux médicaments, notamment en leur indiquant comment utiliser correctement les agents


[legende-image]65[/legende-image] Axe 2 : Rechercher les facteurs associés aux effets indesirables et à l'efficacité du médicament

 
 

COLLABORATIONS